Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Total Current Liabilities (2017 - 2026)

Inspire Medical Systems' Total Current Liabilities history spans 10 years, with the latest figure at $89.4 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 40.88% to $89.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $89.4 million, a 40.88% increase, with the full-year FY2025 number at $96.1 million, up 8.54% from a year prior.
  • Total Current Liabilities hit $89.4 million in Q1 2026 for Inspire Medical Systems, down from $96.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for INSP hit a ceiling of $110.8 million in Q3 2025 and a floor of $43.2 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $72.3 million across 5 years, with a median of $70.0 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: soared 122.26% in 2022 and later decreased 12.06% in 2025.
  • Tracing INSP's Total Current Liabilities over 5 years: stood at $61.2 million in 2022, then grew by 27.65% to $78.1 million in 2023, then grew by 13.31% to $88.5 million in 2024, then rose by 8.54% to $96.1 million in 2025, then fell by 6.91% to $89.4 million in 2026.
  • Business Quant data shows Total Current Liabilities for INSP at $89.4 million in Q1 2026, $96.1 million in Q4 2025, and $110.8 million in Q3 2025.